016 –Treatment Adherence to Somavaratan (VRS-317), a Long-Acting Growth Hormone for Children with Growth Hormone Deficiency (GHD): the VISTA Trial

Background: Efficacy of growth hormone replacement therapy is compromised when patients fail to adhere to prescribed daily injections of recombinant human growth hormone (rhGH); noncompliance has been reported in up to 77% of patients with GHD. Somavaratan is a novel rhGH fusion protein with an extended half-life that allows less frequent dosing, compared to daily rhGH. Clinically meaningful improvements in height velocity and insulin-like growth factor (IGF)-I were previously demonstrated with weekly, twice-monthly, and monthly dosing of somavaratan in pre-pubertal children with GHD (VISTA Trial; NCT01718041).
Source: Journal of Pediatric Nursing - Category: Nursing Authors: Source Type: research